Online citations, reference lists, and bibliographies.
← Back to Search

A Single-blind, Placebo-controlled, Dose-ranging Trial Of Oral Hepatic-directed Vesicle Insulin Add-on To Oral Antidiabetic Treatment In Patients With Type 2 Diabetes Mellitus

W. Geho, Len N Rosenberg, S. Schwartz, J. R. Lau, T. Gana
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Background: The dose response of postprandial plasma glucose (PPG) to add-on, premeal oral hepatic-directed vesicle-insulin (HDV-I), an investigational lipid bio-nanoparticle hepatocyte-targeted insulin delivery system, was evaluated in a 3-test-meal/day model in type 2 diabetes patients. Method: The single-blind, placebo-controlled, dose-escalating trial enrolled 6 patients with HbA1c 8.6 ± 2.0% (70.0 ± 21.9 mmol/mol) and on stable metformin therapy. Patients received oral HDV-I capsules daily 30 minutes before breakfast, lunch, and dinner as follows: placebo capsules, 0.05, 0.1, 0.2, and 0.4 U/kg on days 1, 2, 3, 4, and 5, respectively. Outcome measures were PPG and incremental PPG area under the concentration-time curve (AUC). Results: All 4 doses of oral HDV-I statistically significantly lowered mean PPG (P ≤ .0110 each) and incremental PPG (P ≤ .0352 each) AUC compared to placebo. A linear dose response was not observed. The 0.05 U/kg dose was the minimum effective dose in the dosage range studied. Three adverse events unrelated to treatment were observed. Conclusions: Add-on oral HDV-I 0.05-0.4 U/kg significantly lowered PPG excursions and the dose response curve was flat. These results are consistent with the lack of a linear dose response between portal and systemic plasma insulin concentrations in previous animal and human studies. Oral HDV-I was safe and well tolerated.
This paper references
NIDDM Patients' Fears and Hopes About Insulin Therapy: The basis of patient reluctance
L. Hunt (1997)
Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
A. Wright (2002)
Hepatic-Directed Vesicle Insulin: A Review of Formulation Development and Preclinical Evaluation
W. Geho (2009)
Insulin, insulin-like growth factors and colon cancer: a review of the evidence.
E. Giovannucci (2001)
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.
M. Peyrot (2005)
A single-blind, placebo-controlled, food-dose timing trial of oral HDV-Insulin in patients with type 2 diabetes mellitus
B Geho (2009)
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
R. Turner (1999)
Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.
D. Horwitz (1975)
PI Shishko (1985)
Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus.
R. Henry (1996)
Hepatic-directed vesicle-insulin: evaluation of a novel oral and subcutaneous insulin delivery system in animal models of diabetes (Abstract). Diabetes. 2008;57(suppl 1):A126
B Geho (2008)
JB Field (2009)
Mustafa (1952)
The Role of Nitric Oxide and the Unfolded Protein Response in Cytokine-Induced β-Cell Death
K. Chambers (2008)
The effects of HDV-insulin on carbohydrate metabolism in Type 1 diabetic patients.
S. Davis (2001)
Insulin and risk of cardiovascular disease: a metaanalysis. Circulation
JB Ruige (1998)
Hepatic disposal of biosynthetic human insulin and porcine C-peptide in humans.
P. Bratusch-Marrain (1984)
When oral agents fail: practical barriers to starting insulin
M. Korytkowski (2002)
[Insulin extraction by the isolated perfused rat liver using infusion conditions of a biphasic insulin concentration profile].
H. Brömme (1984)
Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans.
J. Meier (2005)
Comparison of Peripheral and Portal (Via the Umbilical Vein) Routes of Insulin Infusion in IDDM Patients
P. I. Shishko (1992)
Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion.
R. Eaton (1983)
Oral Insulin and Buccal Insulin: A Critical Reappraisal
L. Heinemann (2009)
Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)
R. Turner (1999)
Banting lecture
GM Reaven (1988)
Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery.
L. Heinemann (2001)
Portal and Peripheral Vein Immunoreactive Insulin Concentrations Before and After Glucose Infusion
W. Blackard (1970)
Role of Insulin Resistance in Human Disease
G. Reaven (1988)
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study
康生 大久保 (1995)
Splanchnic and renal metabolism of insulin in human subjects: a dose-response study.
E. Ferrannini (1983)
The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
W. Garvey (1985)
mellitus ( Abstract )
WG Blackard (2008)
Oral Insulin: The Rationale for This Approach and Current Developments
E. Arbit (2009)
Alternative routes of insulin delivery
D. Owens (2003)
Insulin and risk of cardiovascular disease: a meta-analysis.
J. Ruige (1998)
Banting lecture 1988. Role of insulin resistance in human disease.
G. Reaven (1988)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UK Prospective Diabetes Study Group (1998)
A 2-week randomized, active comparator study of two HDV-Insulin routes (SC and oral) and SC human insulin in patients with type 1 diabetes mellitus (Abstract). Diabetes. 2008;57(suppl 1):A124
S Schwartz (2008)
Hepatic - directed vesicle - insulin : evaluation of a novel oral and subcutaneous insulin delivery system in animal models of
B Geho
Resistance to Insulin Therapy Among Patients and Providers Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study
M. Peyrot (2005)
Hepatic and peripheral insulin resistance: A common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus
R. DeFronzo (2004)
Extraction of insulin by liver.
J. Field (1973)

This paper is referenced by
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
C. Ventola (2017)
Advances in oral peptide therapeutics
Daniel J. Drucker (2019)
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches.
D. Brayden (2020)
Aarti Khulbe (2015)
Peptide Drug Design for Diabetes and Related Metabolic Diseases
Niels C. Kaarsholm (2019)
Nanotechnology Approaches to Modulate Immune Responses to Cell-based Therapies for Type 1 Diabetes
S. Wiggins (2020)
Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials.
T. A. Aguirre (2016)
Amphiphilic nucleic acid conjugates for transfection of differentiated intestinal cells
E. V. Moroz (2016)
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola Cl (2017)
Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts.
E. Moroz (2016)
Protein drug delivery: current dosage form profile and formulation strategies
Danilo Costa Geraldes (2019)
Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.
J. Caster (2017)
Applications of Nanomaterials in Human Health
F. Khan (2020)
Emerging Insulin Therapies
Winston Crasto (2016)
Insulin-Loaded Barium Salt Particles Facilitate Oral Delivery of Insulin in Diabetic Rats
Rahela Zaman (2020)
Advances on the formulation of proteins using nanotechnologies
Irene Santalices (2017)
Semantic Scholar Logo Some data provided by SemanticScholar